Investors holding ADSs through brokers will receive ordinary shares automatically; no action is required. Traders should anticipate potential short-term volatility around the transition date due to changes in trading mechanics and investor base adjustments.
ASND drugs
ASND drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $241.71entry
- T+1 · 7mo ago −1.01%α −0.94% · $239.28
- T+5 · 7mo ago +0.51%α −2.67% · $242.95
- T+20 · 6mo ago −2.40%α −9.97% · $235.90
- T+60 · 4mo ago +10.84%α +0.06% · $267.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma A/S announced a transition to a direct listing of its ordinary shares on Nasdaq, replacing its American Depositary Shares (ADSs). Each ADS will be mandatorily exchanged for one ordinary share, with trading of ordinary shares set to begin on April 20, 2026, under the existing ticker ASND. The last day of ADS trading is expected to be April 17, 2026.
Key Facts
- Ascendis Pharma is transitioning from ADSs to direct listing of ordinary shares on Nasdaq.
- The exchange of ADSs for ordinary shares will occur on a 1:1 basis.
- Trading of ordinary shares is expected to commence on April 20, 2026.
- The last day of ADS trading is expected to be April 17, 2026.
- The Bank of New York Mellon will manage the mandatory exchange process.
Financial Impact
No change in underlying equity value; this is a structural change from ADSs to ordinary shares with no dilution or capital raise.
Risk Factors
- Risk that the exchange process encounters delays or operational issues.
- Potential for reduced liquidity or altered trading dynamics post-transition.
- Possible adverse tax implications for certain ADS holders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-147597 |
| Document: 0001193125-26-147597-index-headers.html | 0001193125-26-147597 |
| Document: 0001193125-26-147597-index.html | 0001193125-26-147597 |
| Document: 0001193125-26-147597.txt | 0001193125-26-147597 |
Track record
41 reports on ASND
14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 25 of 27 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers